Skip to main content
Erschienen in: Journal of Thrombosis and Thrombolysis 3/2019

02.01.2019

Assessment of direct oral anticoagulant assay use in clinical practice

verfasst von: Tina M. Gu, David A. Garcia, Daniel E. Sabath

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

There are no clear and consistent guidelines on how to utilize DOAC assays, and reports on the use of DOAC levels in clinical practice is limited. The objective of this study was to analyze why DOAC levels are ordered, how the results affect clinical decision-making, and to determine if DOAC assays are utilized appropriately. This was a retrospective chart review study analyzing 150 dabigatran, rivaroxaban, and apixaban levels performed at a single institution. The majority of DOAC assays were ordered in situations or special patient populations where confirming absence or detecting presence of drug may be useful. The most common indication for ordering assays was prior to an invasive procedure. Most DOAC levels were timed appropriately but peak levels were most likely to be incorrectly ordered. Clinical decisions following level results depended on indication for ordering and were most commonly used to determine whether or not to proceed with an invasive procedure. The results of our study suggest while DOAC assays are generally ordered for useful indications, there is still a lack of understanding of when levels should be drawn and how to interpret DOAC assay results.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Cuker A, Siegal D (2015) Monitoring and reversal of direct oral anticoagulant. Hematology 2015:117–124CrossRefPubMed Cuker A, Siegal D (2015) Monitoring and reversal of direct oral anticoagulant. Hematology 2015:117–124CrossRefPubMed
3.
Zurück zum Zitat Samuelson B, Cuker A, Siegal D, Crowther M, Garcia DA (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest 151:127–138CrossRefPubMed Samuelson B, Cuker A, Siegal D, Crowther M, Garcia DA (2017) Laboratory assessment of the anticoagulant activity of direct oral anticoagulants. Chest 151:127–138CrossRefPubMed
4.
Zurück zum Zitat Adcock DM, Gosselin R (2015) Direct oral anticoagulants in the laboratory: 2015 review. Thromb Res 136:7–12CrossRefPubMed Adcock DM, Gosselin R (2015) Direct oral anticoagulants in the laboratory: 2015 review. Thromb Res 136:7–12CrossRefPubMed
5.
Zurück zum Zitat Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453–461CrossRefPubMed Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Kalebo P, Muelhofer E, Misselwitz F, Eriksson BI (2008) Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 100:453–461CrossRefPubMed
6.
Zurück zum Zitat Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A (2008) A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein DVT Dose Ranging Study. Blood 112:2242–2247CrossRefPubMed Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A (2008) A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein DVT Dose Ranging Study. Blood 112:2242–2247CrossRefPubMed
7.
Zurück zum Zitat van Ryn J, Stangler J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate—a novel reversible oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127CrossRefPubMed van Ryn J, Stangler J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A (2010) Dabigatran etexilate—a novel reversible oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:1116–1127CrossRefPubMed
9.
Zurück zum Zitat Wright C, Brown R, Cuker A (2017) Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice. Int J Lab Hematol 39:31–36CrossRefPubMed Wright C, Brown R, Cuker A (2017) Laboratory measurement of the direct oral anticoagulants: indications and impact on management in clinical practice. Int J Lab Hematol 39:31–36CrossRefPubMed
10.
Zurück zum Zitat Martin K, Moll S (2016) Direct oral anticoagulant drug level testing in clinical practice: a single institution experience. Thromb Res 143:40–44CrossRefPubMedPubMedCentral Martin K, Moll S (2016) Direct oral anticoagulant drug level testing in clinical practice: a single institution experience. Thromb Res 143:40–44CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126:343–348CrossRefPubMed Healey JS, Eikelboom J, Douketis J, Wallentin L, Oldgren J, Yang S, Themeles E, Heidbuchel H, Avezum A, Reilly P, Connolly SJ, Yusuf S, Ezekowitz M (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126:343–348CrossRefPubMed
12.
Zurück zum Zitat Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129:1850–1859CrossRefPubMedPubMedCentral Sherwood MW, Douketis JD, Patel MR, Piccini JP, Hellkamp AS, Lokhnygina Y, Spyropoulos AC, Hankey GJ, Singer DE, Nessel CC, Mahaffey KW, Fox KA, Califf RM, Becker RC (2014) Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 129:1850–1859CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD (2014) Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 124:3692–3698CrossRefPubMedPubMedCentral Garcia D, Alexander JH, Wallentin L, Wojdyla DM, Thomas L, Hanna M, Al-Khatib SM, Dorian P, Ansell J, Commerford P, Flaker G, Lanas F, Vinereanu D, Xavier D, Hylek EM, Held C, Verheugt FW, Granger CB, Lopes RD (2014) Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood 124:3692–3698CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Tripodi A (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost 14:1325–1327CrossRefPubMed Tripodi A (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost 14:1325–1327CrossRefPubMed
15.
Zurück zum Zitat Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost 14:2556–2559CrossRefPubMed Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD (2016) To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost 14:2556–2559CrossRefPubMed
16.
Zurück zum Zitat Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI (2016) The subcommittee on control of anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627CrossRefPubMed Levy JH, Ageno W, Chan NC, Crowther M, Verhamme P, Weitz JI (2016) The subcommittee on control of anticoagulation. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 14:623–627CrossRefPubMed
Metadaten
Titel
Assessment of direct oral anticoagulant assay use in clinical practice
verfasst von
Tina M. Gu
David A. Garcia
Daniel E. Sabath
Publikationsdatum
02.01.2019
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2019
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-018-1793-0

Weitere Artikel der Ausgabe 3/2019

Journal of Thrombosis and Thrombolysis 3/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.